Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01105793 · ClinicalTrials.gov registry record · Phase 2
An Open-Label, MultiCenter Evaluation of the Use of Topically Administered FP1198 in Subjects With Pain Associated With Cyclic Mastalgia
A Phase 2 study, sponsored by FemmePharma Global Healthcare.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT01105793 is a Phase 2 study that has completed, run by FemmePharma Global Healthcare. The registered enrollment target is 20 participants.
The verdict
NCT01105793, a Phase 2 study, has completed, sponsored by FemmePharma Global Healthcare.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety of topical FP1198 for the treatment of moderate to severe cyclic breast pain (cyclic mastalgia) and to examine the clinical activity of FP1198.
Interventions
- DRUG Danazol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2010-06 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01105793
The ClinicalTrials.gov registry entry for NCT01105793 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is FemmePharma Global Healthcare, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Danazol is the first listed.
NCT01105793 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01105793 about?
NCT01105793 is a clinical study titled "An Open-Label, MultiCenter Evaluation of the Use of Topically Administered FP1198 in Subjects With Pain Associated With Cyclic Mastalgia". The purpose of this study is to determine the safety of topical FP1198 for the treatment of moderate to severe cyclic breast pain (cyclic mastalgia) and to examine the clinical activity of FP1198.
What is the current status of trial NCT01105793?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2010-06. Estimated completion is 2011-06.
What interventions are being tested in trial NCT01105793?
The interventions under investigation include: Danazol (DRUG).
Who is sponsoring clinical trial NCT01105793?
This trial is sponsored by FemmePharma Global Healthcare, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.